News Releases

CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clinic UB-311 could offer multiple competitive advantages over licensed passive immunotherapies,

CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, announced that

Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s ability to selectively target aggregated, toxic forms of neurodegenerative proteins CAPE CANAVERAL,

UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further clinical development.

CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress UB-313 to be Featured in Emerging Science Presentation at AAN Annual Meeting CAPE CANAVERAL,